Saakshi Khattri, MD, and Mark Lebwohl, MD, share key insights on recent biologic, topical, and oral treatment approvals for the management of plaque psoriasis.

Peter Lio, MD, explains the importance of having a wide-range of solutions and how he incorporates alternative approaches alongside conventional medicine.

Peter Lio, MD, expands on dosing considerations to treat atopic dermatitis with involvement on the hands and feet for different ages, weights, lifestyles, and more.

Peter Lio, MD, takes a deep dive into the results of the 3 LIBERTY-AD-HAFT study and how it impacts the treatment of hand-foot atopic dermatitis.

Susan Taylor, MD, explained the current state of diversity in clinical trials, what is going well, and opportunities to improve.

Susan Taylor, MD, shared what she wants to know about patients' functionality to treat their atopic dermatitis with hand or foot involvement.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the tolerability and low discontinuation rates of tapinarof for patients in AD clinical trials, as well as discuss the adverse events associated with the drug.

Adelaide A. Hebert, MD, FAAD, shares insight on the eczema area and severity index 75 (EASI75) results from the ADORING 1 and ADORING 2 clinical trials for use of tapinarof in AD.

Expert dermatologists review the validated investigator global assessment for AD (vIGA-AD) response in the ADORING 1 and ADORING 2 trials for tapinarof.

An expert in dermatology reviews the case of a 33-year-old male patient suffering from atopic dermatitis for the past 3 years. He breaks down the panel's conversation on the use of non-steroidal topicals and emphasizes how patient assistance programs can ease burden for patients and providers.

Shawn Kwatra, MD, presents a case involving a 73-year-old African American female seeking treatment for her atopic dermatitis. In this segment Dr Kwatra explains the panels thoughts and rationale behind the prescribed treatments, discussing how each option works and its limitations.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the rapid itch reduction results found in the clinical trials for tapinarof in AD, as well as primary end points of the studies.

Expert dermatologists highlight the patient characteristics in the ADORING 1 and ADORING 2 trials, both focusing on tapinarof for the treatment of AD.

Drs Lisa Swanson and Robert J. Casquejo express their optimism for the future of plaque psoriasis management, sharing their vision for expanded treatment approvals in the pediatric population affected by this condition.

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.

George Han, MD, discusses the latest biologic agents for plaque psoriasis, addressing the balance between efficacy and speed of response. Together with Dr. Leon Kircik, they emphasize the significance of comprehensive data for physician confidence and delve into the clinical utilization of these treatments, stressing the importance of baseline laboratory measurements for all prescribed patients.

Leon Kircik, MD, emphasizes the combined use of emerging topical treatments with systemic or biologic medications and the impact of the treatment vehicle on penetration. He also discusses the potential for longer use of steroidal options by reducing active product quantities through better penetrating vehicles and highlights the potential heightened efficacy of newer topical treatments and the gaps they may fill in the management of this condition.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review clinical trial data for tapinarof cream, 1% in the treatment of AD.